HS-RDT MiP: Clinical Performance of the Histidine Rich Protein 2 (HRP2) Highly Sensitive Rapid Diagnostic Test (HS-RDT) for Malaria Diagnosis in Pregnant Women in Papua New Guinea, A sub-study of Healthy Mothers, Healthy Babies (HMHB)
This project will compare the performance of novel high sensitivity Plasmodium falciparum rapid diagnostic tests with conventional malaria rapid diagnostic tests in pregnant women in Papua New Guinea.
Malaria during pregnancy remains an important public health issue in countries such as Papua New Guinea (PNG). Most cases of malaria in pregnant women do not cause symptoms (sub-clinical) but can contribute to poor outcomes for the mother and baby, such as anaemia, still-birth and low birth weight.
The Bill & Melinda Gates Foundation (BMGF) has supported the development of a new high sensitivity rapid diagnostic tests (HS-RDT) for Plasmodium falciparum infection and this new HS-RDT could be a promising diagnostic and screening test for subclinical malaria during pregnancy.
We are undertaking a cross-sectional survey of 940 pregnant women attending antenatal care to compare the performance of the HS-RDT with that of conventional RDT, light microscopy, LAMP and qPCR for the detection of P. falciparum infection during pregnancy.
This study is conducted in partnership with PNG Institute of Medical Research, East New Britain Provincial Government, National Department of Health and Kirby Institute. The study is sponsored by the Foundation for Innovative and Novel Diagnostics (FIND).
The objective of this study is to provide evidence towards improved detection and therefore treatment of malaria in pregnant women in PNG.
October 2017 – June 2019
The study is ongoing with approximately 600 participants recruited so far. Preliminary data suggests a moderate burden of malaria (18%) and a substantial burden of anaemia (82%) in pregnant women in the study.